KinDex was established in the fall of 2009 to focus on the discovery and development of molecules that modulate key metabolic regulatory networks associated with chronic disease. The principle targets for KinDex are the regulatory nodes embedded in kinase signaling networks that control genetic expression patterns associated with insulin resistance, Type 2 diabetes, cardio metabolic syndrome and obesity. KinDex has a portfolio of lead molecules that have demonstrated a novel mechanism of action in their ability to safely regulate the disturbed regulatory networks related to the etiology of Type 2 diabetes and obesity.

KinDex's unique positioning is based on a history of safe use of these molecules in animals and man as complex mixtures. A large patent portfolio protects these molecules. A first‐generation product, based on tetrahydro‐iso‐alpha acids, is a mixture of three distinct chemical analogs with anti-inflammatory activity. The most potent of these compounds, KDT501, has been isolated from the mixture.

KinDex is currently initiating IND-enabling pharmacology and toxicology studies for KDT501 and intends to file an IND for this clinical candidate in 2011.